Molecular pathology and protein markers for pancreatic cancer:relevance in staging,in adjuvant therapy,in determination of minimal residual disease,and follow-up  

作　　者：Caitlin P.Sok Karunesh Polireddy David A.Kooby 

机构地区：[1]Department of Surgery,Emory University School of Medicine,Atlanta,GA,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第1期56-70,共15页肝胆外科与营养（英文）

摘　　要：The diagnosis and monitoring of disease through the detection of circulating protein biomarkers is a growing field in the practice of oncology.The search for more effective protein biomarkers to aid in the diagnosis and treatment of patients with pancreatic ductal adenocarcinoma(PDAC)remains a valuable area of study,given the aggressive and often occult nature of this malignancy.Liquid biopsies are attractive,as they offer a minimally invasive and cost-effective approach when compared to traditional biopsy methods and imaging modalities used for diagnosis and surveillance.Carbohydrate antigen(CA)19-9 is currently the most commonly used serum protein biomarker for the diagnosis and monitoring of patients with PDAC,but due to its sensitivity and specificity,its utility remains limited.In this review,we examine how circulating protein biomarkers are used in the diagnosis,prognostication,and surveillance of PDAC.We also highlight protein biomarkers that are currently under investigation that have the potential to enhance our ability to detect early-stage malignancies,predict response to therapy,and monitor for recurrence,but these markers require larger prospective validation studies before they can be widely implemented.Continued efforts to identify and validate novel biomarkers will be crucial for improving the management and outcomes of patients with this challenging disease.

关 键 词：Biomarkers pancreatic adenocarcinoma PROTEIN 

分 类 号：R730.2[医药卫生—肿瘤]